There has been regular discussion here and elsewhere about the degree to which new forms of therapy have impacted patient survival since the original approval of docetaxel for treatment of metastatic, castration-resistant prostate cancer (mCRPC). The one thing that has always been clear (at least to your sitemaster) is that one couldn’t just “add up” […]
↧